Boston Scientific Corporation (NYSE:BSX) Stock Has Average Price Target of $70.19

Key Points

• Analysts rate Boston Scientific “Moderate Buy,” with 23 buy ratings, six holds and two sells among 31 firms. The average 12-month price target is $70.19.
• Insiders and institutional investors have been increasing their positions: insiders bought 194,522 shares worth about $9.4 million over the past three months, while institutions own 89.07% of the stock.
• BSX shares opened at $43.74, near their 12-month low, despite the company exceeding quarterly earnings and revenue expectations. Quarterly EPS was $0.86 on $5.44 billion in revenue, with revenue up 7.5% year over year.

Shares of Boston Scientific Corporation (NYSE:BSX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirty-one research firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twenty-three have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $70.19.

Several analysts have recently issued reports on BSX shares. TD Cowen reaffirmed a "buy" rating on shares of Boston Scientific in a report on Thursday, September 17th. Leerink Partners set a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Piper Sandler reiterated an "overweight" rating and set a $65.00 price objective on shares of Boston Scientific in a research report on Friday, June 12th. Finally, Wells Fargo & Company dropped their price objective on shares of Boston Scientific from $50.00 to $48.00 and set an "equal weight" rating for the company in a research note on Wednesday, September 23rd.

Insider Activity

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the firm's stock in a transaction on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction dated Friday, July 31st. The stock was bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently modified their holdings of the stock. QRG Capital Management Inc. lifted its position in Boston Scientific by 129.4% in the second quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider's stock worth $16,031,000 after buying an additional 211,855 shares during the last quarter. Andra AP fonden increased its position in Boston Scientific by 13.9% during the second quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider's stock valued at $8,264,000 after acquiring an additional 23,694 shares during the last quarter. SkyView Investment Advisors LLC bought a new position in Boston Scientific during the second quarter valued at $107,000. Bullseye Investment Management LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at $41,000. Finally, Rench Wealth Management Inc. raised its stake in shares of Boston Scientific by 27.5% in the second quarter. Rench Wealth Management Inc. now owns 27,952 shares of the medical equipment provider's stock valued at $1,193,000 after acquiring an additional 6,033 shares during the period. Institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Down 0.8%

Shares of BSX stock opened at $43.74 on Wednesday. Boston Scientific has a 12-month low of $42.20 and a 12-month high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock's 50-day moving average price is $46.98 and its 200-day moving average price is $52.06. The stock has a market capitalization of $63.40 billion, a price-to-earnings ratio of 17.71, a price-to-earnings-growth ratio of 1.06 and a beta of 0.57.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm's revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts predict that Boston Scientific will post 3.26 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.